Testing SKB571 for MET-mutated advanced lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new drug called SKB571 for people with advanced lung cancer that has a specific change in the MET gene. The goal is to see if the drug can shrink tumors or stop them from growing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 to 75 years old.
- You must have advanced or metastatic non-small cell lung cancer (NSCLC) that has grown or spread after at least one previous treatment.
- Your tumor must have a specific change in the MET gene (like a MET amplification or MET exon 14 skipping mutation).
- You must have at least one tumor that can be measured on a scan (CT or MRI).
- You must be well enough to be up and about at least half the day (ECOG 0 or 1).
- You cannot have active brain metastases (unless they have been treated and are stable) or other serious health problems like uncontrolled infections or heart disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called SKB518 for people with advanced solid tumors that have stopped responding to standard treatments or cannot receive them. The goal is to see if SKB518 can help shrink or control the tumor.
This trial tests a new drug, SKB107, for people whose advanced cancer has spread to the bones and standard treatments no longer work. The goal is to see if SKB107 can help shrink or slow these bone tumors.
This study tests a new drug called SKB118 for advanced solid cancers (any cancer that has spread) that have not responded to standard treatments. The drug is designed to help the immune system fight cancer cells.
This trial tests a new drug called SKB571 in people with advanced non-small cell lung cancer. The goal is to see if it can help shrink tumors or slow cancer growth.
This study tests an experimental drug called SKB571 for people with advanced solid tumors that have not responded to or stopped responding to standard treatments. The goal is to see if SKB571 is safe and to find the right dose.
This trial tests a new drug called SKB571, given in combination with other treatments, for non-small cell lung cancer (a common type of lung cancer). The study aims to see if this combination helps shrink tumors and improve survival.
Hear when a new Non-small Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.